Favorable Mortality Profile of Naltrexone Implants for Opiate Addiction

REFERENCES

• Darke , S , Degenhardt , L and Mattick , R . 2007 . Mortality amongst illicit drug users: epidemiology, causes and intervention , Sydney : Cambridge University Press .
   Google Scholar
• Gronbladh , L and Gunne , L . 1989 . Methadone-assisted rehabilitation of Swedish heroin addicts . Drug Alcohol Depend , 24 : 31 – 7 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K , English , D R , Milne , E and Holman , C D . 1999 . The quantification of mortality resulting from the regular use of illicit opiates . Addiction , 94 : 221 – 9 .
   PubMed Web of Science ®Google Scholar
• Caplehorn , J R , Dalton , M S , Haldar , F , Petrenas , A M and Nisbet , J G . 1996 . Methadone maintenance and addicts' risk of fatal heroin overdose . Subst Use Misuse , 31 : 177 – 96 .
   PubMed Web of Science ®Google Scholar
• Caplehorn , J R and Drummer , O H . 1999 . Mortality associated with New South Wales methadone programs in 1994: lives lost and saved . Med J Aust , 170 : 104 – 9 .
   PubMed Web of Science ®Google Scholar
• Dyer , K R and White , J M . 1997 . Patterns of symptom complaints in methadone maintenance patients . Addiction , 92 : 1445 – 55 .
   PubMed Web of Science ®Google Scholar
• Reece , A S . 2007 . Dentition of addiction in Queensland: poor dental status and major contributing drugs . Aust Dent J , 52 : 144 – 9 .
   PubMed Web of Science ®Google Scholar
• Carter , E F . 1978 . Dental implications of narcotic addiction . Aust Dent J , 23 : 308 – 10 .
   PubMed Web of Science ®Google Scholar
• Fan , J , Hser , Y I and Herbeck , D . 2006 . Tooth retention, tooth loss and use of dental care among long-term narcotics abusers . Subst Abus , 27 : 25 – 32 .
   PubMedGoogle Scholar
• Schreiber , S , Peles , E and Adelson , M . 2008 . Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients . Drug Alcohol Depend , 92 : 79 – 85 .
   PubMed Web of Science ®Google Scholar
• McCarthy , L , Wetzel , M , Sliker , J K , Eisenstein , T K and Rogers , T J . 2001 . Opioids, opioid receptors, and the immune response . Drug Alcohol Depend , 62 : 111 – 23 .
   PubMed Web of Science ®Google Scholar
• Suzuki , S , Carlos , M P , Chuang , L F , Torres , J V , Doi , R H and Chuang , R Y . 2002 . Methadone induces CCR5 and promotes AIDS virus infection . FEBS Lett , 519 : 173 – 7 .
   PubMed Web of Science ®Google Scholar
• Cabral , G A . 2006 . Drugs of abuse, immune modulation, and AIDS . J Neuroimmune Pharmacol , 1 : 280 – 95 .
   PubMed Web of Science ®Google Scholar
• Pillai , R , Nair , B S and Watson , R R . 1991 . AIDS, drugs of abuse and the immune system: a complex immunotoxicological network . Arch Toxicol , 65 : 609 – 17 .
   PubMed Web of Science ®Google Scholar
• Li , Y , Wang , X , Tian , S , Guo , C J , Douglas , S D and Ho , W Z . 2002 . Methadone enhances human immunodeficiency virus infection of human immune cells . J Infect Dis , 185 : 118 – 22 .
   PubMed Web of Science ®Google Scholar
• Gupta , A , Lawrence , A T , Krishnan , K , Kavinsky , C J and Trohman , R G . 2007 . Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes . Am Heart J , 153 : 891 – 9 .
   PubMed Web of Science ®Google Scholar
• Wedam , E F , Bigelow , G E , Johnson , R E , Nuzzo , P A and Haigney , M C . 2007 . QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial . Arch Intern Med , 167 : 2469 – 75 .
   PubMed Web of Science ®Google Scholar
• Ehret , G B , Desmeules , J A and Broers , B . 2007 . Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology . Expert Opin Drug Saf , 6 : 289 – 303 .
   PubMed Web of Science ®Google Scholar
• Darke , S , Kaye , S and Duflou , J . 2006 . Systemic disease among cases of fatal opioid toxicity . Addiction , 101 : 1299 – 305 .
   PubMed Web of Science ®Google Scholar
• Hser , Y I , Gelberg , L , Hoffman , V , Grella , C E , McCarthy , W and Anglin , M D . 2004 . Health conditions among aging narcotics addicts: medical examination results . J Behav Med , 27 : 607 – 22 .
   PubMed Web of Science ®Google Scholar
• Howard , A A , Floris-Moore , M , Arnsten , J H , Santoro , N , Fleischer , N , Lo , Y and Schoenbaum , E E . 2005 . Disorders of glucose metabolism among HIV-infected women . Clin Infect Dis , 40 : 1492 – 9 .
   PubMed Web of Science ®Google Scholar
• Szpanowska-Wohn , A , Kolarzyk , E , Pach , D and Targosz , D . 2004 . [Nutritional status of opiate-dependent persons before and during methadone maintenance therapy] . Przegl Lek , 61 : 339 – 44 .
   PubMedGoogle Scholar
• Howard , A A , Floris-Moore , M , Lo , Y , Arnsten , J H , Fleischer , N and Klein , R S . 2006 . Abnormal glucose metabolism among older men with or at risk of HIV infection . HIV Med , 7 : 389 – 96 .
   PubMed Web of Science ®Google Scholar
• Cooper , O B , Brown , T T and Dobs , A S . 2003 . Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease . Clin Infect Dis , 37 ( Suppl 2 ) : S132 – 6 .
   PubMed Web of Science ®Google Scholar
• Sadeghian , S , Darvish , S , Davoodi , G , Salarifar , M , Mahmoodian , M , Fallah , N and Karimi , A A . 2007 . The association of opium with coronary artery disease . Eur J Cardiovasc Prev Rehabil , 14 : 715 – 7 .
   PubMed Web of Science ®Google Scholar
• Rosen , D , Smith , M L and Reynolds , C F 3rd . 2008 . The prevalence of mental and physical health disorders among older methadone patients . Am J Geriatr Psychiatry , 16 : 488 – 97 .
   PubMed Web of Science ®Google Scholar
• Hser , Y I , McCarthy , W J and Anglin , M D . 1994 . Tobacco use as a distal predictor of mortality among long-term narcotics addicts . Prev Med , 23 : 61 – 9 .
   PubMed Web of Science ®Google Scholar
• Yang , J C , Huang , D and Hser , Y I . 2006 . Long-term morbidity and mortality among a sample of cocaine-dependent black and white veterans . J Urban Health , 83 : 926 – 40 .
   PubMed Web of Science ®Google Scholar
• Gottshcalk , L A , McGuire , F L , Heiser , J F , Dinovo , E C and Birch , H . 1979 . “ Drug abuse deaths in nine cities: A survey report ” . In National Institute of Drug Abuse Ed, Vol. 29, NIDA Research Monograph , 1 – 189 . Bethesda, Maryland, , USA : National Institutes of Health .
   Google Scholar
• Arnold-Reed , D E , Hulse , G K , Hansson , R C , Murray , S D , O'Neil , G , Basso , M R and Holman , C D . 2003 . Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdoses . Addict Biol , 8 : 343 – 50 .
   PubMed Web of Science ®Google Scholar
• Brunton , L L , Lazo , J S and Parker , K L . 2006 . Goodman and Gilman's the Pharmacologic Basis of Therapeutics , Vol. 1 , 2021 New York : McGraw Hill .
   Google Scholar
• Reece , A S . 2008 . Chronic hepatitis as an important contributor to the immunosenescence of parenteral drug addiction . Addiction Biology , 14 : 214 – 226 .
   PubMed Web of Science ®Google Scholar
• Reece , A S . 2007 . Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers . Immun Ageing , 4 : 6 – 15 .
   PubMedGoogle Scholar
• Salvioli , S , Capri , M , Valensin , S , Tieri , P , Monti , D , Ottaviani , E and Franceschi , C . 2006 . Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology . Curr Pharm Des , 12 : 3161 – 71 .
   PubMed Web of Science ®Google Scholar
• Franceschi , C , Bonafe , M , Valensin , S , Olivieri , F , De Luca , M , Ottaviani , E and De Benedictis , G . 2000 . Inflamm-aging. An evolutionary perspective on immunosenescence . Ann N Y Acad Sci , 908 : 244 – 54 .
   PubMed Web of Science ®Google Scholar
• Boren , E and Gershwin , M E . 2004 . Inflamm-aging: autoimmunity, and the immune-risk phenotype . Autoimmun Rev , 3 : 401 – 6 .
   PubMed Web of Science ®Google Scholar
• Wikby , A , Ferguson , F , Forsey , R , Thompson , J , Strindhall , J , Lofgren , S , Nilsson , B O , Ernerudh , J , Pawelec , G and Johansson , B . 2005 . An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans . J Gerontol A Biol Sci Med Sci , 60 : 556 – 65 .
   PubMed Web of Science ®Google Scholar
• Boon , N A , Colledge , N R , Walker , B R and Hunter , A A . 2006 . Davidson's principles and practice of medicine , New York : Churchill Livingstone .
   Google Scholar
• Fauci , A S , Braunwald , E , Kapser , D L , Hauser , S L , Longo , D L and Jameson , J L . 2008 . Harrison's Principles of Internal Medicine, , 17th Edition , Vol. 1 , 2754 New York : McGraw Hill .
   Google Scholar
• Ochshorn , M , Bodner , G , Novick , D M and Kreek , M J . 1989 . The effect of methadone in vitro on natural killer (NK) activity . NIDA Res Monogr , 95 : 522 – 3 .
   PubMedGoogle Scholar
• Novick , D M , Ochshorn , M , Ghali , V , Croxson , T S , Mercer , W D , Chiorazzi , N and Kreek , M J . 1989 . Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients . J Pharmacol Exp Ther , 250 : 606 – 10 .
   PubMed Web of Science ®Google Scholar
• Bruce-Keller , A J , Turchan-Cholewo , J , Smart , E J , Geurin , T , Chauhan , A , Reid , R , Xu , R , Nath , A , Knapp , P E and Hauser , K F . 2008 . Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice . Glia , 56 : 1414 – 27 .
   PubMed Web of Science ®Google Scholar
• Jasinski , D R , Pevnick , J S and Griffith , J D . 1978 . Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction . Arch Gen Psychiatry , 35 : 501 – 16 .
   PubMed Web of Science ®Google Scholar
• Schottenfeld , R S , Pakes , J R , Oliveto , A , Ziedonis , D and Kosten , T R . 1997 . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse . Arch Gen Psychiatry , 54 : 713 – 20 .
   PubMed Web of Science ®Google Scholar
• Ling , W , Wesson , D R , Charuvastra , C and Klett , C J . 1996 . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence . Arch Gen Psychiatry , 53 : 401 – 7 .
   PubMed Web of Science ®Google Scholar
• Carrieri , M P , Amass , L , Lucas , G M , Vlahov , D , Wodak , A and Woody , G E . 2006 . Buprenorphine use: the international experience . Clin Infect Dis , 43 ( Suppl 4 ) : S197 – 215 .
   Web of Science ®Google Scholar
• Johnson , R E , Strain , E C and Amass , L . 2003 . Buprenorphine: how to use it right . Drug Alcohol Depend , 70 : S59 – 77 .
   PubMed Web of Science ®Google Scholar
• Auriacombe , M , Fatseas , M , Dubernet , J , Daulouede , J P and Tignol , J . 2004 . French field experience with buprenorphine . Am J Addict , 13 ( Suppl 1 ) : S17 – 28 .
   PubMed Web of Science ®Google Scholar
• Auriacombe , M , Franques , P and Tignol , J . 2001 . Deaths attributable to methadone vs buprenorphine in France . JAMA , 285 : 45
   PubMed Web of Science ®Google Scholar
• Bell , J R , Butler , B , Lawrance , A , Batey , R and Salmelainen , P . 2009 . Comparing overdose mortality associated with methadone and buprenorphine treatment . Drug Alcohol Depend , 104 : 73 – 7 .
   PubMed Web of Science ®Google Scholar
• Ho , R C , Ho , E C , Tan , C H and Mak , A . 2009 . Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report . Am J Drug Alcohol Abuse , 35 : 199 – 202 .
   PubMed Web of Science ®Google Scholar
• Ho , R C , Ho , E C and Mak , A . 2009 . Cutaneous complications among i.v. buprenorphine users . J Dermatol , 36 : 22 – 9 .
   PubMed Web of Science ®Google Scholar
• Kacinko , S L , Jones , H E , Johnson , R E , Choo , R E and Huestis , M A . 2008 . Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes . Clin Pharmacol Ther , 84 : 604 – 12 .
   PubMed Web of Science ®Google Scholar
• Pettinati , H M , Kampman , K M , Lynch , K G , Xie , H , Dackis , C , Rabinowitz , A R and O'Brien , C P . 2008 . A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence . Addict Behav , 33 : 651 – 67 .
   PubMed Web of Science ®Google Scholar
• Bostwick , J M and Bucci , J A . 2008 . Internet sex addiction treated with naltrexone . Mayo Clin Proc , 83 : 226 – 30 .
   PubMed Web of Science ®Google Scholar
• Dannon , P N , Lowengrub , K , Musin , E , Gonopolsky , Y and Kotler , M . 2007 . 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study . J Clin Psychopharmacol , 27 : 620 – 4 .
   PubMed Web of Science ®Google Scholar
• McCann , D J . 2008 . Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders . Clin Pharmacol Ther , 83 : 627 – 30 .
   PubMed Web of Science ®Google Scholar
• Gerra , G , Fantoma , A and Zaimovic , A . 2006 . Naltrexone and buprenorphine combination in the treatment of opioid dependence . J Psychopharmacol , 20 : 806 – 4 .
   PubMed Web of Science ®Google Scholar
• Hollister , L E . 1978 . Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists . Arch Gen Psychiatry , 35 : 335 – 40 .
   PubMed Web of Science ®Google Scholar
• Brewer , C and Streel , E . 2003 . Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive “immersion” methods of foreign language teaching . Subst Abus , 24 : 157 – 73 .
   PubMedGoogle Scholar
• Reece , A S . 2007 . Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program . Subst Abuse Treat Prev Policy , 2 : 35 – 49 .
   PubMed Web of Science ®Google Scholar
• Krupitsky , E M , Zvartau , E E , Masalov , D V , Tsoi , M V , Burakov , A M , Egorova , V Y , Didenko , T Y , Romanova , T N , Ivanova , E B , Bespalov , A Y , Verbitskaya , E V , Neznanov , N G , Grinenko , A Y , O'Brien , C P and Woody , G E . 2004 . Naltrexone for heroin dependence treatment in St. Petersburg, Russia . J Subst Abuse Treat , 26 : 285 – 94 .
   PubMed Web of Science ®Google Scholar
• Carreno , J E , Bobes , J , Brewer , C , Alvarez , C E , San Narciso , G I , Bascaran , M T and Sanchez del Rio , J . 2002 . 24-hour opiate detoxification and antagonist induction at home–the ‘Asturian method’: a report on 1368 procedures . Addict Biol , 7 : 243 – 50 .
   PubMed Web of Science ®Google Scholar
• Rawson , R A and Tennant , F S Jr. 1984 . Five-year follow-up of opiate addicts with naltrexone and behavior therapy . NIDA Res Monogr , 49 : 289 – 95 .
   PubMedGoogle Scholar
• Digiusto , E , Shakeshaft , A , Ritter , A , O'Brien , S and Mattick , R P . 2004 . Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) . Addiction , 99 : 450 – 60 .
   PubMed Web of Science ®Google Scholar
• Miotto , K , McCann , M J , Rawson , R A , Frosch , D and Ling , W . 1997 . Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts . Drug Alcohol Depend , 45 : 131 – 4 .
   PubMed Web of Science ®Google Scholar
• Landabaso , M A , Iraurgi , I , Jimenez-Lerma , J M , Sanz , J , Fernadez de Corres , B , Araluce , K , Calle , R and Gutierrez-Fraile , M . 1998 . A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts . Addiction , 93 : 739 – 44 .
   PubMed Web of Science ®Google Scholar
• Miotto , K , McCann , M , Basch , J , Rawson , R and Ling , W . 2002 . Naltrexone and dysphoria: fact or myth? . Am J Addict , 11 : 151 – 60 .
   PubMed Web of Science ®Google Scholar
• Ngo , H T , Tait , R J , Arnold-Reed , D E and Hulse , G K . 2007 . Mental health outcomes following naltrexone implant treatment for heroin-dependence . Prog Neuropsychopharmacol Biol Psychiatry , 31 : 605 – 12 .
   PubMed Web of Science ®Google Scholar
• Zagon , I S , Verderame , M F and McLaughlin , P J . 2002 . The biology of the opioid growth factor receptor (OGFr) . Brain Res Brain Res Rev , 38 : 351 – 76 .
   PubMed Web of Science ®Google Scholar
• Anderson , J E . 2000 . A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells . Mol Biol Cell , 11 : 1859 – 74 .
   PubMed Web of Science ®Google Scholar
• Chabi , B , Ljubicic , V , Menzies , K J , Huang , J H , Saleem , A and Hood , D A . 2008 . Mitochondrial function and apoptotic susceptibility in aging skeletal muscle . Aging Cell , 7 : 2 – 12 .
   PubMed Web of Science ®Google Scholar
• Edelberg , J M and Ballard , V L . 2008 . Stem Cell Review Series: Regulating highly potent stem cells in aging: environmental influences on plasticity . Aging Cell , 7 : 599 – 604 .
   PubMed Web of Science ®Google Scholar
• Wang , X , Douglas , S D , Peng , J S , Metzger , D S , O'Brien , C P , Zhang , T and Ho , W Z . 2006 . Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes . J Leukoc Biol , 79 : 1166 – 72 .
   PubMed Web of Science ®Google Scholar
• Gekker , G , Lokensgard , J R and Peterson , P K . 2001 . Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures . Drug Alcohol Depend , 64 : 257 – 63 .
   PubMed Web of Science ®Google Scholar
• Jeffrey , G P , MacQuillan , G , Chua , F , Galhenage , S , Bull , J , Young , E , Hulse , G and O'Neil , G . 2007 . Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants . Hepatology , 45 : 111 – 7 .
   PubMed Web of Science ®Google Scholar
• Gibson , A E , Degenhardt , L J and Hall , W D . 2007 . Opioid overdose deaths can occur in patients with naltrexone implants . Med J Aust , 186 : 152 – 3 .
   PubMed Web of Science ®Google Scholar
• Khong , E and Choy , W . 2007 . Opioid overdose deaths can occur in patients with naltrexone implants . Med J Aust , 187 : 56
   PubMedGoogle Scholar
• Brewer , C L . 2007 . Opioid overdose deaths can occur in patients with naltrexone implants . Med J Aust , 187 : 55
   PubMedGoogle Scholar
• Hulse , G K and Tait , R J . 2007 . Opioid overdose deaths can occur in patients with naltrexone implants . Med J Aust , 187 : 54
   PubMedGoogle Scholar
• Comer , S D , Sullivan , M A , Yu , E , Rothenberg , J L , Kleber , H D , Kampman , K , Dackis , C and O'Brien , C P . 2006 . Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial . Arch Gen Psychiatry , 63 : 210 – 8 .
   PubMed Web of Science ®Google Scholar
• Comer , S D , Collins , E D , Kleber , H D , Nuwayser , E S , Kerrigan , J H and Fischman , M W . 2002 . Depot naltrexone: long-lasting antagonism of the effects of heroin in humans . Psychopharmacology (Berl) , 159 : 351 – 60 .
   PubMed Web of Science ®Google Scholar
• Comer , S D , Sullivan , M A and Hulse , G K . 2007 . Sustained-release naltrexone: novel treatment for opioid dependence . Expert Opin Investig Drugs , 16 : 1285 – 94 .
   PubMed Web of Science ®Google Scholar
• Sullivan , M A , Garawi , F , Bisaga , A , Comer , S D , Carpenter , K , Raby , W N , Anen , S J , Brooks , A C , Jiang , H , Akerele , E and Nunes , E V . 2007 . Management of relapse in naltrexone maintenance for heroin dependence . Drug Alcohol Depend , 91 : 289 – 92 .
   PubMed Web of Science ®Google Scholar
• Sullivan , M A , Vosburg , S K and Comer , S D . 2006 . Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin . Psychopharmacology (Berl) , 189 : 37 – 46 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K , Arnold-Reed , D E , O'Neil , G , Chan , C T and Hansson , R C . 2004 . Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants . Addict Biol , 9 : 67 – 72 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K , O'Neil , G and Arnold-Reed , D E . 2004 . Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user . Int J Gynaecol Obstet , 85 : 170 – 1 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K , O'Neil , G , Hatton , M and Paech , M J . 2003 . Use of oral and implantable naltrexone in the management of the opioid impaired physician . Anaesth Intensive Care , 31 : 196 – 201 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K and O'Neill , G . 2002 . A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user . Aust N Z J Obstet Gynaecol , 42 : 93 – 4 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K , O'Neill , G , Pereira , C and Brewer , C . 2001 . Obstetric and neonatal outcomes associated with maternal naltrexone exposure . Aust N Z J Obstet Gynaecol , 41 : 424 – 8 .
   PubMed Web of Science ®Google Scholar
• Tait , R J , Ngo , H T and Hulse , G K . 2008 . Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment . J Subst Abuse Treat , 35 : 116 – 24 .
   PubMed Web of Science ®Google Scholar
• Ngo , H T , Arnold-Reed , D E , Hansson , R C , Tait , R J and Hulse , G K . 2008 . Blood naltrexone levels over time following naltrexone implant . Prog Neuropsychopharmacol Biol Psychiatry , 32 : 23 – 8 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K , Arnold-Reed , D E , Ngo , H and Reece , A S . 2007 . “ Naltrexone Implants in the Treatment of Heroin Addiction ” . In Trends in Substance Abuse Research , Edited by: McKenna , C R . Vol. 1 , 71 – 88 . New York : Nova .
   Google Scholar
• Hulse , G K , Tait , R J , Comer , S D , Sullivan , M A , Jacobs , I G and Arnold-Reed , D . 2005 . Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants . Drug Alcohol Depend , 79 : 351 – 7 .
   PubMed Web of Science ®Google Scholar
• Hulse , G K and Tait , R J . 2003 . A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in ‘high-risk’ adolescent heroin users . Addict Biol , 8 : 337 – 42 .
   PubMed Web of Science ®Google Scholar
• Degenhardt , L , Gibson , A , Mattick , R P and Hall , W . 2008 . Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy . Drug Alcohol Rev , 27 : 1 – 3 .
   PubMed Web of Science ®Google Scholar
• Verebey , K . 1981 . The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics . NIDA Res Monogr , 28 : 147 – 58 .
   PubMedGoogle Scholar
• Kleber , H D . 1985 . Naltrexone . J Subst Abuse Treat , 2 : 117 – 22 .
   PubMedGoogle Scholar
• Kleber , H D , Kosten , T R , Gaspari , J and Topazian , M . 1985 . Nontolerance to the opioid antagonism of naltrexone . Biol Psychiatry , 20 : 66 – 72 .
   PubMed Web of Science ®Google Scholar
• Gonzalez , J P and Brogden , R N . 1988 . Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence . Drugs , 35 : 192 – 213 .
   PubMed Web of Science ®Google Scholar
• Resnick , R B , Volavka , J , Freedman , A M and Thomas , M . 1974 . Studies of EN-1639A (naltrexone): a new narcotic antagonist . Am J Psychiatry , 131 : 646 – 50 .
   PubMed Web of Science ®Google Scholar
• Kunoe , N , Lobmaier , P , Vederhus , J K , Hjerkinn , B , Hegstad , S , Gossop , M , Kristensen , O and Waal , H . 2009 . Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial . Br J Psychiatry , 194 : 541 – 6 .
   PubMed Web of Science ®Google Scholar
• Reece , AS . 2009 . Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine . J Subst Abuse Treat , 37 : 256 – 65 .
   PubMed Web of Science ®Google Scholar
• Lintzeris , N , Clark , N , Winstock , A , Dunlop , A , Muhleisen , P , Gowing , L , Ali , R , Bell , J , Quigley , A , Mattick , R P , Monheit , B and White , J . 2006 . National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence: Abbreviated , Edited by: Ageing , FDoHa . Vol. 1 , 1 – 22 . Canberra : Australian Government Publishing Service .
   Google Scholar
• Hulse , G K , Arnold-Reed , D E , O'Neil , G , Chan , C T , Hansson , R and O'Neil , P . 2004 . Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants . Addict Biol , 9 : 59 – 65 .
   PubMed Web of Science ®Google Scholar
• Breslow , N E and Day , N E . 1987 . The design and analysis of cohort studies , Lyon : International Agency for Research on Cancer .
   Google Scholar
• Stewart , L M , Henderson , C J , Hobbs , M S , Ridout , S C and Knuiman , M W . 2004 . Risk of death in prisoners after release from jail . Aust N Z J Public Health , 28 : 32 – 6 .
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics . 2007 . “ Deaths–Australia ” . In Australian Bureau of Statistics. 1 , Canberra : Australian Government Publishing Service .
   Google Scholar
• Australian Bureau of Statistics . 2008 . ABS website , Document Canberra : Australian Government Publishing Service . http://www.abs.gov.au/AUSSTATS/[email protected]/DetailsPage3302.02008?Open
   Google Scholar
• Dunbar , J L , Turncliff , R Z , Hayes , S C and Farrell , C B . 2007 . Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence . J Stud Alcohol Drugs , 68 : 862 – 70 .
   PubMed Web of Science ®Google Scholar
• Dunbar , J L , Turncliff , R Z , Dong , Q , Silverman , B L , Ehrich , E W and Lasseter , K C . 2006 . Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone . Alcohol Clin Exp Res , 30 : 480 – 90 .
   PubMed Web of Science ®Google Scholar
• Dean , R L , Todtenkopf , M S , Deaver , D R , Arastu , M F , Dong , N , Reitano , K , O'Driscoll , K , Kriksciukaite , K and Gastfriend , D R . 2008 . Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone . Pharmacol Biochem Behav , 89 : 515 – 22 .
   PubMed Web of Science ®Google Scholar
• Hamilton , R J , Olmedo , R E , Shah , S , Hung , O L , Howland , M A , Perrone , J , Nelson , L S , Lewin , N L and Hoffman , R S . 2002 . Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets . Acad Emerg Med , 9 : 63 – 8 .
   PubMed Web of Science ®Google Scholar
• Reece , S . 2002 . Rapid opioid detoxification in Australia . Acad Emerg Med , 9 : 960 – 2 .
   PubMedGoogle Scholar
• Darke , S . 2003 . Polydrug use and overdose: overthrowing old myths . Addiction , 98 : 711
   PubMed Web of Science ®Google Scholar
• Darke , S and Hall , W . 2003 . Heroin overdose: research and evidence-based intervention . J Urban Health , 80 : 189 – 200 .
   PubMed Web of Science ®Google Scholar
• Darke , S , Mattick , R P and Degenhardt , L . 2003 . The ratio of non-fatal to fatal heroin overdose . Addiction , 98 : 1169 – 71 .
   PubMed Web of Science ®Google Scholar
• Darke , S , Ross , J , Lynskey , M and Teesson , M . 2004 . Attempted suicide among entrants to three treatment modalities for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence and risk factors . Drug Alcohol Depend , 73 : 1 – 10 .
   PubMed Web of Science ®Google Scholar
• Darke , S , Ross , J , Williamson , A , Mills , K L , Havard , A and Teesson , M . 2007 . Patterns and correlates of attempted suicide by heroin users over a 3-year period: findings from the Australian treatment outcome study . Drug Alcohol Depend , 87 : 146 – 52 .
   PubMed Web of Science ®Google Scholar
• Darke , S , Williamson , A , Ross , J and Teesson , M . 2005 . Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS) . Drug Alcohol Depend , 78 : 177 – 86 .
   PubMed Web of Science ®Google Scholar
• Reece , A S . 2007 . Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers . Immunity and Ageing, , 4 : 6
   PubMedGoogle Scholar
• Reece , A S . 2007 . Hair graying in substance addiction . Arch Dermatol , 143 : 116 – 8 .
   PubMed Web of Science ®Google Scholar
• Reece , A S and Davidson , P . 2007 . Deficit of circulating stem—progenitor cells in opiate addiction: a pilot study . Subst Abuse Treat Prev Policy , 2 : 19
   PubMed Web of Science ®Google Scholar
• Kim , T W , Alford , D P , Malabanan , A , Holick , M F and Samet , J H . 2006 . Low bone density in patients receiving methadone maintenance treatment . Drug Alcohol Depend , 85 : 258 – 62 .
   PubMed Web of Science ®Google Scholar
• Wang , M , Zhang , J , Spinetti , G , Jiang , L Q , Monticone , R , Zhao , D , Cheng , L , Krawczyk , M , Talan , M , Pintus , G and Lakatta , E G . 2005 . Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats . Am J Pathol , 167 : 1429 – 42 .
   PubMed Web of Science ®Google Scholar
• Kirkpatrick , B , Messias , E , Harvey , P D , Fernandez-Egea , E and Bowie , C R . 2008 . Is schizophrenia a syndrome of accelerated aging? . Schizophr Bull , 34 : 1024 – 32 .
   PubMed Web of Science ®Google Scholar
• Aldington , S , Harwood , M , Cox , B , Weatherall , M , Beckert , L , Hansell , A , Pritchard , A , Robinson , G and Beasley , R . 2008 . Cannabis use and risk of lung cancer: a case-control study . Eur Respir J , 31 : 280 – 6 .
   PubMed Web of Science ®Google Scholar
• Zhang , Z F , Morgenstern , H , Spitz , M R , Tashkin , D P , Yu , G P , Marshall , J R , Hsu , T C and Schantz , S P . 1999 . Marijuana use and increased risk of squamous cell carcinoma of the head and neck . Cancer Epidemiol Biomarkers Prev , 8 : 1071 – 8 .
   PubMed Web of Science ®Google Scholar
• Sidney , S , Quesenberry , C P Jr. , Friedman , G D and Tekawa , I S . 1997 . Marijuana use and cancer incidence (California, United States) . Cancer Causes Control , 8 : 722 – 8 .
   PubMed Web of Science ®Google Scholar
• Reece , A . 2007 . Lifetime prevalence of cervical neoplasia in addicted and medical patients . Aust N Z J Obstet Gynaecol , 47 : 419 – 23 .
   PubMed Web of Science ®Google Scholar
• Rao , R E , Wojnicki , F H , Coupland , J , Ghosh , S and Corwin , R L . 2008 . Baclofen, raclopride, and naltrexone differentially reduce solid fat emulsion intake under limited access conditions . Pharmacol Biochem Behav , 89 : 581 – 90 .
   PubMed Web of Science ®Google Scholar
• Reid , L D . 1985 . Endogenous opioid peptides and regulation of drinking and feeding . Am J Clin Nutr , 42 : 1099 – 132 .
   PubMed Web of Science ®Google Scholar
• Reece , A S . 2008 . Experience of road and other trauma by the opiate dependent patient: a survey report . Subst Abuse Treat Prev Policy , 3 : 10
   PubMed Web of Science ®Google Scholar
• Reece , A S . 2009 . Chronology and patterns of psychiatric morbidity in substance dependent and medical patients . Australasian Psychiatry , 17 : 170 – 171 .
   Web of Science ®Google Scholar